A cross-sectional, multi-country, observational study of adult patients with respiratory diseases in the Asia Pacific region. - APBORD

MSD Pharmaceuticals Pvt Ltd0 个研究点目标入组 5,250 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•A subject must meet all the criteria listed below to be eligible.
•1.Each subject (or subjects legal representative) must be willing and able to provide written informed consent for the study.
•2.Each subject must be greater than equal to 18 years of age. A subject may be of either sex, and any race or ethnicity.
•3.Each subject must have presented to the study site to receive care for a new or existing diagnosis of asthma, allergic rhinitis, COPD or rhinosinusitis.
•Each subject must be capable of reading and/or comprehending one of the languages of the Informed Consent Form (ICF) and patient survey documents.

•A subject meeting any of the exclusion criteria listed below must be excluded from participating in the study:
•The subject has participated in any interventional clinical study within the 12 weeks prior to entering the current study.
•The subject or a family member is among the personnel of the investigational or Sponsor staff directly involved with this study.
•The subject was screened and consented (enrolled) to participate in this study at a previous visit to the physician or at any other study site.

发起方

MSD Pharmaceuticals Pvt Ltd